Manuella Kaster

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7304359/publications.pdf

Version: 2024-02-01

79 papers	3,754 citations	126858 33 h-index	133188 59 g-index
79 all docs	79 docs citations	79 times ranked	5245 citing authors

#	Article	IF	Citations
1	Role of heme oxygenase-1 in the antidepressant-like effect of ursolic acid in the tail suspension test. Journal of Pharmacy and Pharmacology, 2022, 74, 13-21.	1.2	3
2	BDNF Levels According to Variations in the CACNA1C Gene: Sex-Based Disparity. Cellular and Molecular Neurobiology, 2022, , 1.	1.7	1
3	Physical exercise prevents amyloid Î²1â^'40-induced disturbances in NLRP3 inflammasome pathway in the hippocampus of mice. Metabolic Brain Disease, 2021, 36, 351-359.	1.4	22
4	Sex-dependent role of CD300f immune receptor in generalized anxiety disorder. Brain, Behavior, & Immunity - Health, 2021, 11, 100191.	1.3	3
5	Low doses of ketamine and guanosine abrogate corticosterone-induced anxiety-related behavior, but not disturbances in the hippocampal NLRP3 inflammasome pathway. Psychopharmacology, 2021, 238, 2555-2568.	1.5	11
6	The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway. Journal of Psychiatric Research, 2021, 144, 118-128.	1.5	15
7	Individual history of winning and hierarchy landscape influence stress susceptibility in mice. ELife, 2021, 10, .	2.8	24
8	Glibenclamide treatment prevents depressive-like behavior and memory impairment induced by chronic unpredictable stress in female mice. Behavioural Pharmacology, 2021, 32, 170-181.	0.8	3
9	Stress and signaling pathways regulating autophagy: From behavioral models to psychiatric disorders. Experimental Neurology, 2020, 334, 113485.	2.0	16
10	Agmatine potentiates antidepressant and synaptic actions of ketamine: Effects on dendritic arbors and spines architecture and Akt/S6 kinase signaling. Experimental Neurology, 2020, 333, 113398.	2.0	7
11	CD300f immunoreceptor is associated with major depressive disorder and decreased microglial metabolic fitness. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6651-6662.	3.3	21
12	Cholecalciferol abolishes depressive-like behavior and hippocampal glucocorticoid receptor impairment induced by chronic corticosterone administration in mice. Pharmacology Biochemistry and Behavior, 2020, 196, 172971.	1.3	19
13	Subthreshold doses of guanosine plus ketamine elicit antidepressant-like effect in a mouse model of depression induced by corticosterone: Role of GR/NF-ÎºB/IDO-1 signaling. Neurochemistry International, 2020, 139, 104797.	1.9	17
14	Inosine prevents hyperlocomotion in a ketamine-induced model of mania in rats. Brain Research, 2020, 1733, 146721.	1.1	4
15	Temperament traits moderate the relationship between Childhood Trauma and Interleukin 1Î² profile in young adults. Psychoneuroendocrinology, 2020, 116, 104671.	1.3	6
16	Transcultural adaptation and psychometric evaluation of the Brazilian version of the Temporal Experience of Pleasure Scale (TEPSâ€“Br). Trends in Psychiatry and Psychotherapy, 2020, , .	0.4	0
17	Leptin polymorphism rs3828942: risk for anxiety disorders?. European Archives of Psychiatry and Clinical Neuroscience, 2019, 271, 1141-1148.	1.8	1
18	Protective Effects of Ursolic Acid Against Cytotoxicity Induced by Corticosterone: Role of Protein Kinases. Neurochemical Research, 2019, 44, 2843-2855.	1.6	15

#	Article	IF	Citations
19	Potential Role of Vitamin D for the Management of Depression and Anxiety. CNS Drugs, 2019, 33, 619-637.	2.7	76
20	S104. Impact of CD300f Immunoreceptors in Microglia Phenotype and Behavioural Alterations Relevant to Major Depressive Disorder. Biological Psychiatry, 2019, 85, S337-S338.	0.7	0
21	Curcumin in Depressive Disorders. , 2019, , 459-477.		0
22	Levels of 25-hydroxyvitamin D3, biochemical parameters and symptoms of depression and anxiety in healthy individuals. Metabolic Brain Disease, 2019, 34, 527-535.	1.4	11
23	Impact of genetic variations in ADORA2A gene on depression and symptoms: a cross-sectional population-based study. Purinergic Signalling, 2019, 15, 37-44.	1.1	32
24	Natural Polyphenols and Terpenoids for Depression Treatment: Current Status. Studies in Natural Products Chemistry, 2018, 55, 181-221.	0.8	11
25	Depression and peripheral inflammatory profile of patients with obesity. Psychoneuroendocrinology, 2018, 91, 132-141.	1.3	73
26	F162. NLRP3 Polymorphism and Peripheral Levels of Interleukin-1Î² in Patients With Major Depressive Disorder. Biological Psychiatry, 2018, 83, S301-S302.	0.7	0
27	Agmatine potentiates neuroprotective effects of subthreshold concentrations of ketamine via mTOR/S6 kinase signaling pathway. Neurochemistry International, 2018, 118, 275-285.	1.9	18
28	Caffeine Reverts Memory But Not Mood Impairment in a Depression-Prone Mouse Strain with Up-Regulated Adenosine A2A Receptor in Hippocampal Glutamate Synapses. Molecular Neurobiology, 2017, 54, 1552-1563.	1.9	55
29	Vaccinium virgatum fruit extract as an important adjuvant in biochemical and behavioral alterations observed in animal model of metabolic syndrome. Biomedicine and Pharmacotherapy, 2017, 88, 939-947.	2.5	15
30	NLRP3 inflammasome-driven pathways in depression: Clinical and preclinical findings. Brain, Behavior, and Immunity, 2017, 64, 367-383.	2.0	295
31	Ursolic acid affords antidepressant-like effects in mice through the activation of PKA, PKC, CAMK-II and MEK1/2. Pharmacological Reports, 2017, 69, 1240-1246.	1.5	22
32	Signaling pathways underlying the antidepressant-like effect of inosine in mice. Purinergic Signalling, 2017, 13, 203-214.	1.1	28
33	Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases. CNS Drugs, 2017, 31, 1029-1041.	2.7	44
34	Glutamatergic system and mTOR-signaling pathway participate in the antidepressant-like effect of inosine in the tail suspension test. Journal of Neural Transmission, 2017, 124, 1227-1237.	1.4	18
35	Curcumin in depressive disorders: An overview of potential mechanisms, preclinical and clinical findings. European Journal of Pharmacology, 2016, 784, 192-198.	1.7	51
36	Adenosine A2A Receptors in the Amygdala Control Synaptic Plasticity and Contextual Fear Memory. Neuropsychopharmacology, 2016, 41, 2862-2871.	2.8	75

#	Article	IF	Citations
37	Novel approaches for the management of depressive disorders. European Journal of Pharmacology, 2016, 771, 236-240.	1.7	35
38	Preventive effects of blueberry extract on behavioral and biochemical dysfunctions in rats submitted to a model of manic behavior induced by ketamine. Brain Research Bulletin, 2016, 127, 260-269.	1.4	29
39	The Met allele of BDNF Val66Met polymorphism is associated with increased BDNF levels in generalized anxiety disorder. Psychiatric Genetics, 2015, 25, 201-207.	0.6	37
40	Association of interleukin-10 levels with age of onset and duration of illness in patients with major depressive disorder. Revista Brasileira De Psiquiatria, 2015, 37, 296-302.	0.9	19
41	Preventive Effect of Cecropia pachystachya Against Ketamine-Induced Manic Behavior and Oxidative Stress in Rats. Neurochemical Research, 2015, 40, 1421-1430.	1.6	22
42	Caffeine acts through neuronal adenosine A _{2A} receptors to prevent mood and memory dysfunction triggered by chronic stress. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 7833-7838.	3.3	248
43	Leptin in Depressive Episodes: Is There a Difference between Unipolar and Bipolar Depression?. Neuroendocrinology, 2015, 101, 82-86.	1.2	21
44	Creatine, similarly to ketamine, affords antidepressant-like effects in the tail suspension test via adenosine A1 and A2A receptor activation. Purinergic Signalling, 2015, 11, 215-227.	1.1	34
45	Impaired adrenal medullary function in a mouse model of depression induced by unpredictable chronic stress. European Neuropsychopharmacology, 2015, 25, 1753-1766.	0.3	18
46	Cognitive psychotherapy treatment decreases peripheral oxidative stress parameters associated with major depression disorder. Biological Psychology, 2015, 110, 175-181.	1.1	18
47	Genotype 1 of hepatitis C virus increases the risk of major depression: a 12-week prospective study. General Hospital Psychiatry, 2015, 37, 283-287.	1.2	7
48	Chronic Unpredictable Stress Induces Catecholaminergic System Changes in Mouse Adrenal Gland. , 2014, , 205.		0
49	Immune dysfunction in bipolar disorder and suicide risk: is there an association between peripheral corticotropinâ€releasing hormone and interleukinâ€1Î²?. Bipolar Disorders, 2014, 16, 741-747.	1.1	49
50	Gender-based differences in oxidative stress parameters do not underlie the differences in mood disorders susceptibility between sexes. European Psychiatry, 2014, 29, 58-63.	0.1	46
51	Prevalence of depression symptoms and serum levels of interleukinâ€6 in hemodialysis patients. Psychiatry and Clinical Neurosciences, 2014, 68, 275-282.	1.0	19
52	Antidepressant-like effects of aqueous extract from Cecropia pachystachya leaves in a mouse model of chronic unpredictable stress. Brain Research Bulletin, 2014, 108, 10-17.	1.4	27
53	Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats. European Journal of Pharmacology, 2014, 724, 132-139.	1.7	79
54	Catecholamine Release Modulation by Adenosine Through A2a Receptors in Mouse Chromaffin Cells in Culture. , 2014, , 244-245.		0

#	Article	IF	Citations
55	Catecholamine Release Modulation by Adenosine through A2AReceptors in Mouse Chromaffin Cell Culture. , 2014, , 235.		0
56	Reduced Serum Levels of Neuron Specific Enolase (NSE) in Drug-NaÃ¯ve Subjects with Major Depression and Bipolar Disorder. Neurochemical Research, 2013, 38, 1394-1398.	1.6	21
57	The antidepressant-like effect of inosine in the FST is associated with both adenosine A1 and A2A receptors. Purinergic Signalling, 2013, 9, 481-486.	1.1	44
58	Interleukin-1Î² is associated with depressive episode in major depression but not in bipolar disorder. Journal of Psychiatric Research, 2013, 47, 2011-2014.	1.5	45
59	The impact of cognitive behavioral therapy on IL-6 levels in unmedicated women experiencing the first episode of depression: A pilot study. Psychiatry Research, 2013, 209, 742-745.	1.7	38
60	Involvement of NMDA receptors in the antidepressant-like action of adenosine. Pharmacological Reports, 2012, 64, 706-713.	1.5	27
61	Depressive-like behavior induced by tumor necrosis factor-Î± in mice. Neuropharmacology, 2012, 62, 419-426.	2.0	252
62	Diacerein decreases visceral pain through inhibition of glutamatergic neurotransmission and cytokine signaling in mice. Pharmacology Biochemistry and Behavior, 2012, 102, 549-554.	1.3	34
63	Adenosine receptors and brain diseases: Neuroprotection and neurodegeneration. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 1380-1399.	1.4	361
64	Moderate Long-Term Modulation of Neuropeptide Y in Hypothalamic Arcuate Nucleus Induces Energy Balance Alterations in Adult Rats. PLoS ONE, 2011, 6, e22333.	1.1	44
65	Antidepressant-like effect of the organoselenium compound ebselen in mice: Evidence for the involvement of the monoaminergic system. European Journal of Pharmacology, 2009, 602, 85-91.	1.7	74
66	Antidepressant-like effect of folic acid: Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway. European Journal of Pharmacology, 2008, 598, 37-42.	1.7	65
67	Folic acid administration produces an antidepressant-like effect in mice: Evidence for the involvement of the serotonergic and noradrenergic systems. Neuropharmacology, 2008, 54, 464-473.	2.0	118
68	Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1549-1556.	2.5	116
69	Antidepressant-like effect of the extract from leaves of Schinus molle L. in mice: Evidence for the involvement of the monoaminergic system. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 421-428.	2.5	106
70	The inhibition of different types of potassium channels underlies the antidepressant-like effect of adenosine in the mouse forced swimming test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 690-696.	2.5	42
71	Antidepressant-like effect of lamotrigine in the mouse forced swimming test: Evidence for the involvement of the noradrenergic system. European Journal of Pharmacology, 2007, 565, 119-124.	1.7	62
72	Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. European Journal of Pharmacology, 2007, 575, 87-93.	1.7	33

#	Article	IF	Citations
73	Pharmacological evidence for the involvement of the opioid system in the antidepressant-like effect of adenosine in the mouse forced swimming test. European Journal of Pharmacology, 2007, 576, 91-98.	1.7	43
74	Mechanisms involved in the antinociception caused by melatonin in mice. Journal of Pineal Research, 2006, 41, 382-389.	3.4	77
75	Antidepressantâ€like effect of lectin from Canavalia brasiliensis (ConBr) administered centrally in mice. Pharmacology Biochemistry and Behavior, 2006, 85, 160-169.	1.3	54
76	Involvement of nitric oxideâ€“cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. International Journal of Neuropsychopharmacology, 2005, 8, 601.	1.0	86
77	Effects of potassium channel inhibitors in the forced swimming test: Possible involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathway. Behavioural Brain Research, 2005, 165, 204-209.	1.2	94
78	Involvement of 5-HT1A receptors in the antidepressant-like effect of adenosine in the mouse forced swimming test. Brain Research Bulletin, 2005, 67, 53-61.	1.4	68
79	Adenosine administration produces an antidepressant-like effect in mice: evidence for the involvement of A1 and A2A receptors. Neuroscience Letters, 2004, 355, 21-24.	1.0	130